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1. Introduction  
Spontaneous rectal cancers usually arise as a consequence of somatic mutation of the APC 
gene followed by other mutations (K-ras mutation, DCC inactivation and p53 gene 
mutation), well-known today as the adenoma-to-carcinoma sequence (Kinzler & Vogelstein, 
1996). This sequence covers most spontaneous rectal cancers (80%). However mutation(s) in 
DNA repair genes; the MSH1, MSH2, PMS1, PMS2 are also involved in certain fraction of 
rectal tumours, leading to microsatellite instability (Kim et al., 2006). Today about seventy 
different mutations, including important oncogenes and tumour suppressor genes, are 
known to be present in various colorectal cancers (Sjoblom, 2008). Colorectal cancers also 
exhibit changes in DNA methylation with hypermethylation of CpG islands and 
hypomethylation of oncogenes (Kang, 2007). The mutated cancer genotype is associated 
with changed expression in many genes, as has been demonstrated by powerful microarray 
analysis and Real Time PCR technology. It is now well known that mutations and changed 
DNA methylation pattern, as well as changes of mRNA transcription, are accompanied by 
changes of expression in certain microRNAs. 
2. Background information 
2.1 Therapy of rectal cancer 
Surgical excision is the primary treatment. However locally advanced rectal cancer (LARC, 
T3,T4,N0, or TX, N1, N2) needs supportive pre-operative and postoperative therapy. This 
therapy combines pre-operative linear accelerator irradiation and chemotherapy with 
fluoropyrimidines, such as 5-fluorouracil or capecitabine. Postoperative therapy is based on 
adjuvant treatment with further doses of fluoropyrimidines combined with biological 
treatment where appropriate. (for details, see Lee et al., 2008). Supportive therapy is 
necessary for downsizing and downstaging of LARC tumours before surgery. Downsizing 
and downstaging during pre-operative treatment increases the frequency of operations in 
which the sphincter is saved (Lee et al., 2008). Moreover, this pre-operative treatment may 
also lower the risk of cancer dissemination during surgery. Seventy to seventy-five percent 
of patients react with some downstaging and downsizing of rectal tumours following 
chemoradiotherapy before surgery. However, only about 30% of patients exhibit substantial 
downstaging and downsizing tumour response and only 10-20% of them exhibit complete 
tumour eradication through this pre-operative procedure (Kim, 2007). The reasons for these 
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differences in tumour response are not yet well understood. It is widely known that 
irradiation or anticancer drug treatment of cell lines causes extensive changes in gene 
expression as well as changes in certain microRNAs, and that differences in responsiveness 
of cell lines to irradiation and drug treatment are dependent on individual genetic 
background and the presence of certain mutations in certain oncogenes or tumour 
suppressor genes. However information is very limited concerning molecular events 
associated with tumour response to therapy in vivo.  
2.2 MicroRNA- basic information  
MicroRNAs, also known as miRNAs, are small regulatory molecules (19-25 nucleotides long) 
that play an important role at the post-translational level of gene regulation (Ambros, 2001). 
MicroRNAs are widespread molecules, present in all eukaryotic organisms studied to date, 
including fungi, green plants and animals. MicroRNAs were first described in Western 
literature in 1993 and were found to play an irreplaceable regulatory role in the spatiotemporal 
development of the nematode worm Caenorhabditis elegans (Lee, 1993). Some 1800 different 
microRNAs and their sequence variants have been discovered in humans to date. Mature 
molecules are processed from primary transcripts (pri-miRNAs) that are 1000 nucleotides or 
more long (Winter et al., 2009). Primary microRNA transcripts originate either at intergenic 
locations or from intronic sequences of certain actively transcribed genes. If located at intronic 
sites, microRNAs may be transcribed both as sense and antisense sequences of these actively 
transcribed genes. Primary transcripts are processed in the nucleus by the specific nuclease 
Drosha to form approx. 70-nucleotide-long double-stranded pre-miRNAs (see also Scheme 1. 
for details). These pre-mature microRNA molecules are transported through nuclear pores of 
the nuclear membrane via the exportin 5 complex to the cytoplasm. Once within the 
cytoplasm, pre-miRNAs are processed by nuclease Dicer to form 19-25-nucleotide long, 
double-stranded molecules of sense miRNA and antisense miRNA*. Single stranded 
microRNAs finally bind to an RNA-silencing protein complex (known as RISC) and target 
complementary sequences present at the 3' end of the mRNA molecules. If a complex of target 
mRNA-miRNA-RISC is generated, translation inhibition of mRNA occurs. In humans 
approximately one-third of mRNA coding genes also contain target sites for one or more of 
several different types of microRNA. The same target sequence for a given microRNA may be 
present in mRNAs transcribed from many different genes. 
Thus one type of microRNA may regulate many different genes simultaneously. Moreover, 
since several target sites for different microRNAs may be present in one mRNA and its 
gene, one gene can be regulated by several microRNAs. Thus post-translational regulation 
of gene expression by microRNAs is a very complex process; it is not yet fully understood. 
2.3 MicroRNAs as regulatory molecules 
MicroRNAs were originally discovered as important regulators of spatiotemporal 
development in the nematode worm Caenorhabditis elegans (Slack and Ruvkun, 1997) and 
were thought to have a canalisation function (i.e. phenotype stabilizing) in the organism 
(Hornstein and Shomron, 2006). Other authors later found that microRNAs may also have a 
buffering function in the regulation of gene expression (Cui and Yu, 2007). It is accepted 
today that microRNAs may play both the above roles (Wu et al., 2009). MicroRNAs are 
integrated into many regulatory circuits influencing cell cycle progression, genome 
maintenance, apoptosis and differentiation (Ambros, 2004; Re et al., 2009). 
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Scheme 1. MicroRNA processing. 
2.4 MicroRNAs and exosomes 
The term "exosome" has become somewhat ambiguous over time. It was originally applied 
to the extrachromosomal DNA elements mediating non-Mendelian inheritance of certain 
traits in the fruit fly Drosophila melanogaster (Fox et al., 1970). Later the term "exosome 
complex" came to designate the supermolecular aggregates responsible for RNA 
degradation in eukaryotic cells (Mitchell, 1997). Finally, since the 1980’s, the term "exosome 
vesicles" or "exosomes" came to be consistently applied to the membrane vesicles that are 
exported from the cytoplasmic membrane of mammalian cells to the surrounding milieu 
(Trams et al., 1981). Any further mention of exosomes in this paper refers to this third 
meaning of the term. Exosomes may function as tools of intercellular communication 
(Simons et al., 2009). They may influence such an important processes as immunity 
responses (Lee et al., 2011). Moreover, since exosomes are exported to the bloodstream, they 
may transfer information to cells that are distant from the site at which the exosomes 
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themselves are produced in the body. Thus something like "long distance calls" may occur 
by means of exosome extravasation by one kind of cell at one body site and exosome 
intravasation to other cells at a second site, and vice versa. Exosomes may transport not only 
proteins, but also mRNAs, DNAs and microRNAs. It has been demonstrated that the 
information carried can be exploited by cells that intravasate exosomes. Intravasated mRNA 
can be translated to a functional product, while transferred microRNA may inhibit 
translation of target proteins in cells to which exosome microRNAs have been 
admitted(Keller et al., 2011). Apart from the establishment of exosomes as a new platform 
for intercellular communication, exosomes can serve as a diagnostic tool, since cancer cells 
extravasate a different spectrum of microRNAs compared to normal cells (Keller et al., 
2011). Moreover, microRNAs in exosomes secreted to the blood are relatively stable 
(Wittman et al., 2011). It is well proven that plasma microRNA profiles from cancer patients 
have different spectra of microRNAs compared to microRNA profiles from healthy people 
(Kosaka et al., 2011). However, multi-centre studies are required to investigate the clinical 
diagnostic validity of results obtained to date, since the majority of the studies have 
involved relatively small numbers of clinical samples, usually from fewer than a hundred 
patients. 
2.5 MicroRNA expression profiles in cancer 
It is widely accepted that microRNA expression profiles are different in all types of cancer 
when compared with non-tumourous tissue counterparts studied to date, including for 
example sarcoma, glioma, carcinoma and haematological malignancies (Volinia, 2006) 
MicroRNAs actively involved in carcinogenesis operate by inhibiting tumour suppressor 
genes or by activation of cellular proto-oncogenes. Both the suppressing role and the 
activating role are most frequently mediated by the inhibitory role of microRNAs in 
translation of target mRNAs containing complementary sequences. Thus the first mode of 
miRNA action (suppression) is mediated directly, while the second mode, i.e. proto-
oncogene activation, must take place indirectly through negative feedback, inhibiting 
translation of certain proto-oncogene suppressors. However, some microRNAs may well 
activate target genes by an as-yet-undisclosed mechanism (Iwasaki and Tomari, 2009). 
2.6 Changes of microRNA expression in rectal cancer  
Several microRNAs exhibit specific differences of expression levels in rectal and colon 
cancer when compared with healthy or non-tumourous tissue. Colorectal cancers show 
decreased levels of miR-143, miR-145 and Let-7a-1 microRNAs (Michael, 2003; Akao, 2006). 
These microRNAs are known to function as tumour suppressors since they inhibit 
expression of the known cellular proto-oncogenes c-myc and K-ras (Akao, 2006). Levels of 
these microRNAs are also lowered in other cancers, including haematological malignancies 
(Akao, 2007). A further microRNA, miR-21, acts as an oncogene, since it inhibits apoptotic 
processes and induces cancer cell proliferation (Si, 2007). This microRNA is significantly 
overexpressed in higher states of colon and rectal cancers and higher miR-21 levels are 
associated with worse prognosis (Schetter, 2008). Recently miR-95 was found to be 
overexpressed in approximately 50% of CRC tumours (Huang, 2011). This microRNA 
promotes proliferation by direct repression of sorting nexin 1 (Huang, 2011). Nowadays, 
several dozen different microRNAs are known to exhibit changed expression levels in 
association with CRC (Volinia, 2006; Bandres, 2006).  
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2.7 Potential role of microRNAs in modulating anticancer drug and radiation response 
Drug resistance and the comparative impact of radiation has been fairly frequently studied 
in cancer cells in vitro (Bandres, 2007; DiGennaro, 2009). However, our knowledge of the 
molecular events that take place in response to anticancer drugs and radiation in human 
tumours in vivo is very limited, and this is even more true of microRNA expression changes 
induced by these events. It has been demonstrated that several microRNA levels are 
significantly changed in response to 5-fluorouracil in CRC cell lines in vitro (Rossi, 2007). 
MicroRNAs miR-27a a miR-451 have been found to stimulate expression of multidrug 
resistance protein MDR1, thus increasing resistance to several anticancer drugs in vitro 
(Zhu, 2008). Two further important microRNAs, miR-181b and Let-7g, have been found to 
be involved in responses to the S-1 anticancer drug in colon cancer cells (Nakajima, 2006). 
Several studies have also been dedicated to the role which 5-fluorouracil therapy may play 
in the induction of microRNA level changes in clinical samples of cancers. It has been 
disclosed that 5-fluorouracil therapy induces changes in several microRNAs in gastric 
cancer (Takagi, 2009) and breast cancer (Salter, 2008). One of our previously-published 
papers addressed the induction of miR-125b and miR-137 in rectal cancer in response to pre-
operative chemoradiotherapy (Svoboda et al., 2008). A German research group has recently 
noted that miRNAs are returned to normal levels after successful pre-operative 
chemoradiotherapy and subsequent surgery of locally advanced rectal cancer (Drebber et 
al., 2011). 
2.8 MicroRNAs as prognostic and predictive markers 
This subject has recently been reviewed by (Dong et al., 2011). The expression levels of 
several microRNAs are associated with the TNM state of rectal cancer and might be used 
for prognosis. MicroRNA miR-21 is upregulated in rectal cancer and higher levels are 
associated with node positivity, metastasis, and poor survival (Kulda 2010, Schetter 2008, 
Slaby 2007). High miR-21 stromal expression levels are associated with short disease-free 
intervals in stage II colorectal cancer patients (Nielsen et al., 2011). MicroRNAs miR-143 
and miR-145 are downregulated in rectal cancer. Lower levels are related to large tumour 
sizes and to disease-free intervals (Slaby et al., 2007; Motoyama et al., 2009; Wang et al., 
2009). MiR-31 and miR-106a are upregulated in CRC and reflect tumour states (Bandres et 
al., 2006; Schetter 2008). Several microRNAs have also been found to be associated with 
tumour response to therapy or response of cell lines to anticancer drugs. Patients who 
responded to fluoropyrimidine S-1 showed lower levels of miR-181b and Let-7g. However 
neither microRNA was associated with survival (Nakajima 2006). MiR-215 increased 
resistance of cancer cell lines to methotrexate and tomudex (Song 2010). We have 
previously noted that microRNAs miR-125b and miR-137 are upregulated in response to 
pre-operative chemoradiotherapy, and higher levels of expression have been associated 
with worse response to therapy (Svoboda 2008). Various modalities of X-irradiation may 
give rise to different microRNA expression in vitro (Ahmed 2009). Ragusa suggested that 
microRNAs let-7b, let 7e and miR-17-3p might be potential predictors of cetuximab 
resistance (Ragusa et al 2010). MicroRNAs are embedded in exosomes in blood plasma. 
Since molecules embedded in exosomes are relatively stable for a period of time (up  
to several days), microRNA expression may simply be monitored from patients' blood 
(Ng 2009). 
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3. Aims of the study 
The aim of this study was to test the possible involvement of the miR-21, miR-125b, miR-137 
and miR-145 in tumour responses to standard pre-operative capecitabine 
chemoradiotherapy. A further aim was to evaluate the possibility of using mentioned 
microRNAs as predictors of antiacancer drug response or as prognostic markers. 
4. Patients and methods 
4.1 Patients 
Patients aged 33-76 years, median age being 59, 31 man and 12 woman, ECOG performance 
status of 0-2, who had histologically confirmed locally advanced rectal adenocarcinoma 
(LARC) without distant metastases, stages II-III (cT3 - cT4, cN0, cM0 or T2 –T4, cN+,cM0) 
according to lUCC (Wittekind, 2002) were included in the study. The Ethics Committee of 
the Masaryk Memorial Cancer Institute approved the treatment protocol. All patients gave 
written informed consent.  
4.2 Methods 
Preoperative capecitabine was administered orally, at a dose of 825 mg/m2 twice a day, two 
hours prior to radiotherapy for approximately 5.5 weeks from the first to the last day of 
radiotherapy. Radiation therapy was given in conventional fractionation in locally curative 
dosage. The daily fraction dose was 1.8 Gy, applied in five days per week up to cumulative 
dose of 45 Gy, boosting up to 50,4 Gy, during the period of 5.5 weeks. The standard total 
rectal resection or amputation (Faerden, Naimy et al. 2005), leaving tumor-free resection 
margins including total mesorectal excision (TME) was performed within the 6th week after 
completion of radiotherapy. Clinical cTNM stage (preceding a therapy) was based on the 
endorectal ultrasonography, CT and colonoscopy. Pathological examination after surgery 
involved the former tumor-bearing area and its macroscopic and microscopic description. 
The tumor response to therapy was investigated microscopically. Our department of 
pathology has routinely been using tumor regression (TRG 1-5) criteria adapted to colon 
cancer (Bouzourene et al., 2002). Tumor biopsies (1-3 mm3) were taken before starting 
therapy and again after two-week therapy. Tumor samples were immersed immediately in 
RNA Later solution (Quiagen GmbH, Germany). The RNAs from bioptic samples were 
isolated by the standard Trizol method (Chomczynski 1993). RNAs were quantified using 
Eppendorf spectrophotometer (Eppendorf, Germany). Quality of RNA was tested by 
standard denaturing electrophoresis. The microRNA levels in pre-treatment and treatment 
samples were determined by means of stem-loop RT-Real Time PCR and TaqMan detection 
(Chen, Ridzon et al. 2005). Reverse transcription of cDNA was performed using gene-
specific primers, TaqMan MicroRNA Reverse Transcription Kit and 10 ng RNA according to 
TaqMan MicroRNA Assay Protocol. Stem-loop RT primer (50nM), 1x RT buffer, 10mM 
dNTP each, RNase inhibitor 0.19ul, MultiScribe reverse transcriptase 1ul, water and RNA 
were mixed in 15ul final reaction volume and incubated for 30 min at 16oC, 30 min at 42oC, 5 
min at 85oC, cooled and kept at 4oC. Real Time PCR mix contained 10ul TaqMan Universal 
Master Mix No Amp Erase UNG, 1ul 20x Assay Mix from TaqMan MicroRNA Assay Kit 
(both from Applied Biosystems, Foster City, USA), RT product 1.33ul and water in final 
volume of 20ul.Real Time PCR was performed on Applied Biosystems 7000 instrument in a 
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96- well optical plate under following conditions: 95oC 10min initial denaturation, 40 cycles 
of 95oC for 15s and 60oC for 40s. RNU6B RNA was used as an reference endogenous 
control. The threshold cycle CT was determined using default instrument settings. Adjacent 
non-tumorous mucosa before treatment was used as a calibrator.  
4.3 Data analysis 
We used comparative CT method approach (2 -delta delta Ct) for the calculation of relative 
miRNA expression (Applied Biosystems User Bulletin #2, P/N 4303859). Expression of 
miRNA was related to RNU6B RNA as an endogenous active reference. The data before 
starting therapy were designated as a control group versus a sample group representing 
data two weeks after starting therapy. Standard statistical analyses were calculated using 
MedCalc and Statistica version 7 software. 
5. Results  
5.1 Clinical data 
Table 1 summarizes data of patients under study. Forty- three patients were recruited. Nine 
patients exhibited recurrent disease within follow-up period. Eight of them died. One 
patient died from comorbidity. All recurrent diseases occured within the three-years period 
after surgery. 
 
Patients Attribute % Value range 
man/woman 31/12 74/26   
Age (median and range)     59 (33-76) 
Patients undergoing surgery 42 98   
Number of recidives 9 21   
Median follow-up (months)     49 
Local recidives 2 5   
Median disease-free period to local recidive     23 (10-36) 
 Distant metastases 7 17   
Median disease-free period to distant metastase recurrence     19 (10-58) 
Secondary malignities 0 0   
Number of deaths 9 21   
Deaths owing to cancer recurrence 8 19   
 a) local 2 5   
 b) distant 6 14   
Comorbidities 1 2   
Postoperative complications 0 0   
 
Table 1. Basic clinical data of recruited patients. 
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5.2 Non-parametric distribution of statistical data 
Statistical analysis of microRNA expression levels determined by standard comparative CT 
method shows non-parametric distribution of data (Shapiro-Wilk and Lilliefors tests). We 
therefore used non-parametric testing for all data (Wilcoxon paired test and Mann-Whitney-
U-test). 
5.3 MicroRNA expression levels 
Our results show that median levels of miR-21, miR-125b and miR-145 were upregulated 
two weeks after starting therapy. Expression level of miR-137 is not included since we 
already published its upregulation (Svoboda et al., 2008).  
 
 
miR21 No.sa
mples
Median 95% confidence 
interval 
p Mann-Whitney U-
test (two- sided) 
p Wilcoxon 
(paired, two-
sided) 
before 42 9,318 0,057 26,173 0,1129 0,0464 
two weeks 35 16,450 5,637 29,651   (N=35) 
a) miR-21 induction 
 
 
Mann-Whitney  
U-test (two- sided) 
No.samples Median 95% confidence í interval p  
miR125b before 42 0,463 0,045 5,618 0,03054 
miR125b , two weeks 35 1,173 0,129 8,282   
b) miR-125b induction 
 
 
Mann-Whitney U-test 
(two- sided)  
No.samples Median 95% confidence interval p  
miR145 before 42 0,145 0,078 1,279 0,000001 
miR145 , two weeks 35 1,661 0,483 9,383   
c) miR-145 induction 
Table 2. a,b,c. Induction of microRNA expression by the preoperative chemoradiotherapy. 
MicroRNAs exhibited extensive intertumoral level variability both before treatment and in 
samples taken two weeks after starting therapy (see 95% confidence intervals in Tables 3.,4.). 
The observation of frequent upregulation after starting therapy may support our initial 
hypothesis that miRNA levels tend to change to normal levels after efficient tumor 
destruction as both miR125b and miR137 are known to be down-regulated either in  
CRC lines or colorectal and breast carcinomas (Iorio, Ferracin et al. 2005). Nevertheless, miR-
21 is upregulated in most colorectal cancers and functions as an oncogene (Nielsen et al., 
2011).  
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miR-145 before miR-145  two weeks
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Table 3. Variability of microRNA miR-145 expression levels before and two weeks after 
starting preoperative chemoradiotherapy 
 
TRG1,2 before TRG1,2  two weeks
TRG3-5 before TRG3-5  2 two weeks
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35 
 
Table 4. a) Box-plot graph of the relative expression of miR-21. Role of tumour regression 
grade TRG. 
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Therefore, we investigated whether the changes of miRNA levels are reflected within 
immediate tumor responses and downstaging. As table 2 shows., miR-21 is upregulated in 
rectal cancer two weeks after starting preoperative chemoradiotherapy. Moreover, there are 
statistically significant differences between responsive (TRG1,2) and non-responsive group 
(TRG 3-5) before starting therapy and different ypT stages respectively (tables 4. and 5.).  
 
Mann-Whitney U-test 
(two-sided) 
Median relatve 
expression 
95% confidence interval p 
 miR21 TRG1,2 before 2,312 1,731 7,438 0,014 
 miR21 TRG3-5 before 13,404 5,897 26,173  
 miR21 TRG1,2 two wks. 5,849 5,637 16,641 0,077 
 miR21 TRG3-5 two wks. 17,749 7,863 29,651  
Table 4. b) Median levels of relative miR-21 expression. Role of tumour regression grade 
TRG. 
 
 
ypT01 before ypT23 before 
ypT0,1  two 
weeks 
yPT23  two 
weeks 
0 
5 
10 
15 
20 
25 
30 
35 
 
 
Table 5. a) The Box-plot graph of relative miR-21 expression. Role of ypT. 
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Mann-Whitney U-test (two-sided) Patients ypT0,1 Patients ypT2,3 p 
ypT0,1 vs. ypT2,3 before  16 26 0,1088 
ypT0,1 vs.  
yPT2,3 two weeks 
10 25 0,0185 
Table 5. b) Median levels of relative miR-21 expression. Role of ypT. 
 
 
0 10 20 30 40 50 60
Months
0,6
0,7
0,7
0,8
0,8
0,9
0,9
1,0
1,0
 
 
 
Log-Rank Test p = ,15754 
Table 6. Kaplan-Meyer graph of disease-free survival. Red line: patients with high-level 
miR-21 tumours suffer from recurrent disease. Green line: patients with low-level miR-21 
tumours. Median level of relative miR-21 expression is the cut-off value discriminating 
between high-level miR-21 tumours and low-level miR-21 tumours respectively. 
Although 125b is upregulated in all ypT groups, the highest and the only statistically 
significant change is observed in the group ypT3 patients (no downstaging). It is well 
known that T3/4 stage or node involvement is usually associated with worse prognosis than 
T0-T2, N0. Therefore, higher induction of miR125 is associated with a worse prognosis. 
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miR-125b Patients 
Median 
expression 
95% confidence 
interval 
p (Wilcoxon 
paired) 
 TRG12 before 25 0,393 0,092 2,761 0,005 
TRG12 two weeks 21 0,905 0,329 9,646 (N=21)  
 TRG3-5 before 17 0,694 0,188 1,414 0,059 
 TRG 3-5 two weeks 14 1,131 0,189 3,204 (N=14)  
Table 7. a) Dependence of induced miR-125b levels on the tumour regression grade. 
Wilcoxon paired test 
 
Mann-Whitney U- test TRG1-2 TRG3-5 p 
TRG12 vs TRG3-5 before 25 17 0,109 
 TRG12 vs TRG3-5 two weeks 21 14 0,391 
Table 7. b) Dependence of induced miR-125b levels on the tumour regression grade. 
Comparison of different TRG groups.  
 
ypT0,1 before ypT0,1  two weeks  
ypT2 before ypT2 two weeks
ypT3 before ypT3 two weeks  
-2 
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8 
10 
12 
 
 
Table 8. a) Dependence of induced miR-125b levels on the tumour state ypT. Box-plot graph. 
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There are profound differences of miR125b levels between ypT0,1, and ypT3 patient groups 
after starting therapy (Table 8). Patients with low stage tumours have lower miRNA 
induction than patients with more advanced cancers. These results tell us that we should 
use carefully term oncogene or tumour suppresor in connection with certain miRNAs. 
MicroRNA miR125b is downregulated in several cancers and may be therefore considered a 
tumor suppressor from this point of view. However, in this study we show no downstaging 
and less regression (bad response) in the tumors with the highest upregulation of miR125b 
level two weeks after starting therapy. Non-responding tumors exhibited induction of 
miR125b level close to and above normal levels of adjacent non-tumorous mucosa.  
 
miR-125b Patients Median 95% confidence interval p Wilcoxon (paired, two-
sided) 
 ypT0,1 before 16 0,158 0,092 1,464 0,4446 
 ypT0,1 two weeks 10 0,362 0,011 5,011   
 ypT2 before  14 0,662 0,045 2,796 0,0843 
 ypT2 two weeks  13 1,186 0,129 9,646   
 ypT3 before 12 0,463 0,054 5,618 0,0164 
 ypT3 two weeks 12 1,828 0,073 8,282   
Table 8. b) Dependence of induced miR-125b levels on the tumour state ypT. Wilcoxon 
paired test. 
 
Mann-Whitney U-test (two-sided) 
Patients 
ypT0,1 
Patients 
ypT2 ypT3
p 
ypT0,1 vs pT2 before 16 14 0,1223 
ypT0,1 vs pT2 two weeks 10 13 0,1375 
ypT0,1 vs pT3 before 16 12 0,1971 
ypT0,1 vs pT3 two weeks 10 12 0,0295 
Table 8. c) Dependence of induced miR-125b levels on the tumour state ypT. Comparison of 
different ypT states by Mann-Whitney two-sided test. 
Our results show that miR137 is significantly upregulated in both responder groups (Table 
9.a). However there is no association of miR137 induction with tumour response (Table 9.b). 
Interestingly, on the contrary to the above-mentioned miR125b although upregulated, 
miR137 in tumors never reached the original median value of normal tissue. We therefore 
speculate that low miR137 levels may be important to maintain tumour state. 
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 miR-137 Patients Median Confidence interval p (Wilcoxon 
paired) 
TRG1,2 beforer 25 0,037 0,003 0,688 0,027 
TRG1,2 two weeks 21 0,162 0,012 0,766 (N=21)  
TRG3-5 before 17 0,035 0,006 0,646 0,006 
TRG3-5 two weeks 14 0,301 0,005 0,655 (N=14)  
Table 9. a) Dependence of induced miR-137 levels on the tumour regression grade. Wicoxon 
paired test. 
 
Mann-Whitney U-test (two-sided) Patients 
TRG1,2 
Patients 
TRG3-5 
p 
TRG12 vs. 3-5 before 25 17 0,538 
TRG12 vs. 3-5 two weeks 21 14 0,373 
Table 9. b) Comparison of miR-137 levels between responders and non-responders. Mann-
Whitney two-sided test. 
 
 
TRG1,2 before TRG1,2  two weeks 
 TRG3-5 before TRG3-5 two weeks
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Table 10. a) Dependence of induced miR-145 levels on the tumour state ypT. 
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MicroRNA miR-145 is significantly upregulated both in responders and non-responders 
respectively (Tables 10 a,b). Moreover, miR-145 has significantly higher expression in 
tumors from responders before therapy (Table 10 c). Similar effect we can observe in the ypT 
state groups: patients with ypT0,1 tumours (better prognosis) have higher miR-145 levels. 
This is in accordance with known tumour-supressive role of miR-145. 
 
miR-145 Valid N Median 
expresion 
95% confidence 
interval  
p (Wilcoxon 
paired t.) 
TRG1,2 before 25 0,226 0,078 3,279 0,0021 
TRG1,2 two weeks 21 1,248 0,126 9,383 (N=21) 
TRG3-5 before 17 0,115 0,075 0,518 0,0003 
TRG3-5 two weeks 14 1,886 0,812 9,646 (N=14)  
 
Table 10. b) Dependence of induced miR-145 levels on the tumour regression grade. 
 
Mann-Whitney U-test Patients TRG
1,2 
Patients TRG 3-
5 
p (two sided) 
TRG 1,2 vs.3-5 before 25 17 0,013 
TRG1,2 vs. 3-5 two weeks 25 17 0,274 
 
Table 10. c) Dependence of induced miR-145 levels on the tumour regression grade. 
Comparison of diffferent TRG groups. 
 
miR-145 Valid N Median 95% confidence interval p Wilcoxon  
(paired, two sided 
test) 
 ypT0,1 before 16 0,226 0,111 1,338 0,0004 
 ypT0,1 two weeks 10 1,586 0,483 9,383 (N=10)  
 ypT2 before 14 0,132 0,078 3,279 0,1361 
 ypT2 two weeks 13 1,227 0,126 9,646 (N=13)  
 ypT3 before 12 0,133 0,075 0,518 0,0010 
 ypT3 two weeks 12 1,621 0,812 4,691 (N=12)  
 
Table 10. d) Dependence of induced miR-145 levels on the tumour state ypT. 
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ypN0 before ypN0  two weeks 
ypN1,2 before ypN1,2  two weeks 
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Table 11. a) Dependence of pre-therapeutic and induced miR-145 levels on the node state 
pN. Box-plot graph. 
 
miR-145 Patients Median 95% confidence interval p Wilcoxon  
(paired, two sided t.) 
 ypN0 before 25 0,226 0,075 3,279 0,0010 
 ypN0 two weeks  23 1,586 0,126 9,646 (N=23) 
 ypN1,2 before 17 0,115 0,078 0,518 0,0003 
 ypN1,2 two weeks  12 1,357 0,812 9,646 (N=12) 
Table 11. b) Dependence of pre-therapeutic and induced miR-145 levels on the node state 
pN . 
 
Mann-Whitney U-test (two-sided) Patients pN0 Patients pN1,2 p 
 ypN0 vs. ypN1,2 before 25 17 0,0283 
 ypN0 vs. ypN1,2 two weeks  23 12 0,8196 
Table 11. c) Dependence of pre-therapeutic and induced miR-145 levels on the node state 
pN. Comparison of ypN0 and ypN1,2 groups. 
We have also investigated the role of node involvement. Table 11 shows that miR-145 levels 
of ypN0 patients differ significantly from ypN1,2 before starting therapy. The upregulation 
of miR-125b was published previously (Svoboda, 2008).  
6. Discussion 
MicroRNAs play an important part in the regulation of many important cellular processes 
and target approximately a third of expressed genes. It is therefore reasonable to assume 
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that microRNAs would be influenced by such a massive cell-destructive process as pre-
operative chemoradiotherapy. This pre-operative treatment degrades the proliferative 
potential of many cancer cells and leads to extensive tumour regression in many patients 
(Bouzourene et al., 2002). Among the microRNAs we have been investigating, miR-21 
exhibits the highest difference in expression levels considered in terms of response to 
therapy. While tumours that respond well contain low miR-21 levels, non-responders have 
high miR-21 levels (median level as cut-off value discriminating between low and high 
levels). It is crucial to note that these differences are already pronounced in samples taken 
from tumours before starting therapy (p=0.014). Therefore, miR-21 is not only a known 
prognostic factor, but it may also be used also as a predictor of tumour response to pre-
operative chemoradiotherapy. This is not a surprising fact, since miR-21 is a known anti-
apoptotic and pro-proliferative factor and is currently recognized as an oncogene (Zhang et 
al., 2008). We also show in our preliminary data that high miR-21 levels might be associated 
with short disease-free survival and recurrent disease, as may be seen on the Kaplan-Meyer 
graph (Table 6). Patients with high-level miR-21 tumours suffer from recurrent disease 
while patients with low-level miR-21 tumours are all disease-free within the five-year 
follow-up period. However since only a small number of patients has been monitored to 
date, statistical significance according to log-rank test remained only p=0.15 and more 
patients must be recruited in order to obtain statistically valid data. Epithelial-to-
mesenchymal transition (EMT) is a primary event leading to the prometastatic behaviour of 
cancer cells (Gregory et al., 2008). TGF-beta-induced EMT leads to upregulation of miR-21 in 
a model system of human keratinocytes in vitro (Zavadil et al., 2007). Induction of miR-21 
leads to pro-invasive behaviour in breast cell lines in vitro and metastasizing of tumours 
related to those lines in animals in vivo (Zhu et al., 2008). This effect is mediated by miR-21 
inhibition of tropomyosin 1 activity (Zhu et al., 2008). Tropomyosin 1 is a tumour 
suppressor. MiR-21 also inhibits PDCD4 and maspin, further important regulators: (Zhu et 
al., 2008). Our data are in accordance with these in vitro findings, since high levels of miR-21 
are associated with recurrent and refractory disease in our study. MicroRNA miR-125b is an 
ortholog of Lin-4 microRNA of the worm Caenorhabditis elegans (Ambros, 2003). High levels 
of this microRNA prolong the lifespan of the worm, probably by influencing the insulin 
metabolic pathway (Boehm, 2006). High levels of miR-125b give rise to similar effects in 
rectal cancer: tumours with highly-induced miR-125b survive chemoradiotherapy 
intervention and are refractory, while low-MiR-125b-level tumours are partially or 
completely destroyed. On the basis of the analogy with the nematode worm and of our 
findings, we suggest that miR-125b supports mechanisms necessary for cell survival that are 
undoubtedly initiated as an adaptation to the chemical and radiation stress induced as a 
consequence of preoperative chemoradiotherapy. On the other hand, miR-125b is known to 
suppress proto-oncogenes ERBB2 and ERBB3 expression in vitro (Scott et al., 2007). ERBB2 
and ERBB3 are known pro-metastatic and pro-proliferative factors. We speculate that this 
opposite effect of miR-125b may co-exist in parallel with the previously-mentioned effect 
and may provide a base for explanation of the fact that, while only 30-40% of tumours are 
extensively shrinked, the frequency of metastasis and recurrent disease is lower in patients 
who have undergone preoperative chemoradiotherapy versus patients who did not in the 
past when this treatment modality was not yet established (Lee, 2008). The level of miR-137 
is frequently suppressed in glioblastoma and CRC (Silber et al., 2008). This is caused by 
aberrant methylation of CpG islands near coding genes (Kozaki, 2008). Here, the observed 
induction of miR-137 is in accordance with the fact that this microRNA suppresses G0 to G1 
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transition (Silber et al., 2008). Suppression of cell growth is a general process accompanying 
chemoradiation treatment. Tables 9 a,b show that miR-137 levels are upregulated in all 
tumours despite TRG. We may therefore expect that miR-137 induction is a part of the 
general process of adaptation to chemical and radiation stress. However therapy-induced 
miR-137 levels never achieve their original levels, i.e. those present in non-cancerous tissue 
counterpart. We may therefore assume that miR-137 might be a tumour suppressor and that 
lower miR-137 expression helps to maintain the transformed phenotype. This is also 
supported by the finding that miR-137 directly targets carboxy-terminal binding protein I 
(CtBPI) to inhibit epithelial-to-mesencyhmal transition and induce apoptosis in melanoma 
cells (Deng et al., 2011). We therefore speculate that, although miR-137 does not contribute 
to an immediate effect of tumour regression, it may lower later cancer recurrence by 
inhibiting epithelial-to-mesenchymal transition processes. The relevance of this speculative 
construction is also supported by the fact that transfection of pre-miR-137 (a microRNA 
precursor molecule) stops proliferation and induces differentiation in glioblastoma cells in 
vitro (Silber et al., 2008). MicroRNA miR-145 is downregulated in many cancers, including 
carcinomas of the bladder, lung and stomach (Takagi et al., 2009; Cho et al., 2009; Ichimi, 
2009). Levels of this microRNA are also downregulated in CRC (Wang&Zhou, 2009). It is 
recognised as a tumour suppressor, supported by the fact that transfected miR-145 
precursors inhibit the growth of lung cancer cells in vitro and also inhibit the growth of 
MCF-7 breast cancer-derived cells (Cho et al., 2009). Moreover, miR-145 upregulation 
induces apoptosis in MCF-7 cells (Wang& Bian et al., 2009). According to our results, miR-
145 is upregulated after starting pre-operative chemoradiotherapy. In the light of the 
tumour suppressor role, we assume that upregulated miR-145 participates in vivo (in vitro 
model analogy) in the inhibition of cancer cell growth. Our results show that microRNA 
miR-145 levels before starting therapy well reflect therapy outcome. Therefore, miR-145 may 
be used as a predictor of response to pre-operative chemoradiotherapy. This accords with 
the recent finding of German authors (Drebber et al., 2011). 
7. Conclusion 
MicroRNAs miR-21, miR-125b, miR-137 and miR-145 all display up-regulation of expression 
induced by preoperative chemoradiotherapy of locally advanced rectal cancer. Among 
microRNAs we have been investigating, miR-21 and miR-145 exhibit the highest differences 
in expression levels considered in terms of response to therapy. MiR-21 as well as miR-145 
may be used as potential predictive and prognostic markers. 
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